Literature DB >> 34286473

Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Eun-Joo Shin1, Ji Hoon Jeong2, Yeonggwang Hwang1, Naveen Sharma1,2, Duy-Khanh Dang1,3, Bao-Trong Nguyen1, Seung-Yeol Nah4, Choon-Gon Jang5, Guoying Bing6, Toshitaka Nabeshima7, Hyoung-Chun Kim8,9.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease with a high prevalence, approximately 1 % in the elderly population. Numerous studies have demonstrated that methamphetamine (MA) intoxication caused the neurological deficits and nigrostriatal damage seen in Parkinsonian conditions, and subsequent rodent studies have found that neurotoxic binge administration of MA reproduced PD-like features, in terms of its symptomatology and pathology. Several anti-Parkinsonian medications have been shown to attenuate the motor impairments and dopaminergic damage induced by MA. In addition, it has been recognized that mitochondrial dysfunction, oxidative stress, pro-apoptosis, proteasomal/autophagic impairment, and neuroinflammation play important roles in inducing MA neurotoxicity. Importantly, MA neurotoxicity has been shown to share a common mechanism of dopaminergic toxicity with that of PD pathogenesis. This review describes the major findings on the neuropathological features and underlying neurotoxic mechanisms induced by MA and compares them with Parkinsonian pathogenesis. Taken together, it is suggested that neurotoxic binge-type administration of MA in rodents is a valid animal model for PD that may provide knowledge on the neuropathogenesis of PD.
© 2021. The Pharmaceutical Society of Korea.

Entities:  

Keywords:  Animal model; Dopaminergic neurotoxicity; Methamphetamine; Parkinson’s disease

Mesh:

Substances:

Year:  2021        PMID: 34286473     DOI: 10.1007/s12272-021-01341-7

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  271 in total

Review 1.  Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources.

Authors:  Vera Adam-Vizi
Journal:  Antioxid Redox Signal       Date:  2005 Sep-Oct       Impact factor: 8.401

2.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.

Authors:  P Anglade; S Vyas; F Javoy-Agid; M T Herrero; P P Michel; J Marquez; A Mouatt-Prigent; M Ruberg; E C Hirsch; Y Agid
Journal:  Histol Histopathol       Date:  1997-01       Impact factor: 2.303

3.  Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine.

Authors:  S Ares-Santos; N Granado; I Oliva; E O'Shea; E D Martin; M I Colado; R Moratalla
Journal:  Neurobiol Dis       Date:  2011-11-13       Impact factor: 5.996

4.  Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines.

Authors:  Beatriz Alvarez-Castelao; Marc Goethals; Joël Vandekerckhove; José G Castaño
Journal:  Biochim Biophys Acta       Date:  2013-12-03

5.  Methamphetamine-induced increase in striatal p53 DNA-binding activity is attenuated in Cu,Zn-superoxide dismutase transgenic mice.

Authors:  Masato Asanuma; Ikuko Miyazaki; Youichirou Higashi; Jean Lud Cadet; Norio Ogawa
Journal:  Neurosci Lett       Date:  2002-06-14       Impact factor: 3.046

6.  Brain peroxidase and catalase in Parkinson disease.

Authors:  L M Ambani; M H Van Woert; S Murphy
Journal:  Arch Neurol       Date:  1975-02

7.  Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum.

Authors:  O Açikgöz; S Gönenç; B M Kayatekin; N Uysal; C Pekçetin; I Semin; A Güre
Journal:  Brain Res       Date:  1998-11-30       Impact factor: 3.252

8.  Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.

Authors:  Sara Ares-Santos; Noelia Granado; Isabel Espadas; Ricardo Martinez-Murillo; Rosario Moratalla
Journal:  Neuropsychopharmacology       Date:  2013-10-30       Impact factor: 7.853

9.  Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug.

Authors:  Masato Asanuma; Takeshi Tsuji; Ikuko Miyazaki; Ko Miyoshi; Norio Ogawa
Journal:  Neurosci Lett       Date:  2003-11-27       Impact factor: 3.046

10.  Chaperone-mediated autophagy markers in Parkinson disease brains.

Authors:  Lydia Alvarez-Erviti; Maria C Rodriguez-Oroz; J Mark Cooper; Cristina Caballero; Isidro Ferrer; Jose A Obeso; Anthony H V Schapira
Journal:  Arch Neurol       Date:  2010-08-09
View more
  3 in total

1.  Mass spectrometry-based metabolomics in hair from current and former patients with methamphetamine use disorder.

Authors:  Min Jae Seo; Sang-Hoon Song; Suji Kim; Won Jun Jang; Chul-Ho Jeong; Sooyeun Lee
Journal:  Arch Pharm Res       Date:  2021-11-06       Impact factor: 4.946

2.  Atypical Parkinsonism: Methamphetamine may play a role.

Authors:  Mehri Salari; Fatemeh Hojjati Pour; Ronak Rashedi; Masoud Etemadifar
Journal:  Clin Case Rep       Date:  2022-05-05

3.  Differential vulnerability of locus coeruleus and dorsal raphe neurons to chronic methamphetamine-induced degeneration.

Authors:  Yijuan Du; Sanghoon Choi; Alexander Pilski; Steven M Graves
Journal:  Front Cell Neurosci       Date:  2022-07-22       Impact factor: 6.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.